Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer - Wikidata - wikimedia - TriplyDB

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

http://www.wikidata.org/entity/Q24630999

about

A primer on tumour immunology and prostate cancer immunotherapy The Promise of Preventive Cancer Vaccines Immunotherapy for prostate cancer: recent developments and future challenges Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas Immune regulation of bone metastasis Prostate cancer: ESMO Consensus Conference Guidelines 2012 Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients.Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignancies Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer.Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer.Optimizing dendritic cell-based approaches for cancer immunotherapy Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.Proposed mechanisms of action for prostate cancer vaccines.U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.The changing landscape in the treatment of metastatic castration-resistant prostate cancer.The determinants of tumour immunogenicity.Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.Cancer immunotherapy products: regulatory aspects in the European Union.Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma.Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors.Perspectives on treatment of metastatic castration-resistant prostate cancer.A pharmacologic perspective on newly emerging T-cell manipulation technologies.Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions.Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.Genetic cancer vaccines: current status and perspectives.Prostate cancer vaccines in clinical trials.Management of advanced prostate cancer in senior adults: the new landscape.Prostate cancer vaccines.Clinical trials in cellular immunotherapy for brain/CNS tumors.Optimal therapy sequencing in metastatic castration-resistant prostate cancer.Translational Approaches towards Cancer Gene Therapy: Hurdles and Hopes.The utility of prostate-specific antigen in the management of advanced prostate cancer.Recent advances revolutionize treatment of metastatic prostate cancer.Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer.Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.Prostate cancer vaccines in combination with additional treatment modalities.

P2860

Q26765697-3B86B25A-F78F-4E4A-AF84-D6CCBF2EDB63 Q26783742-E8AA1425-2B45-423F-93FF-4302027A4505 Q26852388-926888CA-A715-44ED-A3C2-F79738FAD2F9 Q26862551-88EF804F-57BD-4AC5-885A-ED080935D026 Q27005871-561CADDF-EE5F-4E8E-9D7C-15E62B52E71C Q27022847-910BBF42-D11B-4D91-A1EE-38342229E128 Q31157425-78B800A1-1F93-4B9B-A640-8013D36FD604 Q33361158-EE870427-50F7-4CB9-9484-B8678D9D3316 Q33844570-2B0F19DC-7447-43AB-AE4C-AAA1E89CA8B7 Q34290252-F0E017ED-3FBB-4FDB-8C1F-80FB8BF69BEE Q34321844-F01819D2-2D84-499C-9B43-135483053DFE Q34637535-CEC20CB1-8139-4038-A10A-2E6E39AEF328 Q34787165-1E4B469F-D993-4AF4-82B4-70247670DBBD Q35063621-E5BE79B6-C9E8-48B3-BBFE-9D9023C188EC Q35174754-56CA2CB3-4CE2-447B-A590-93BE73498772 Q35915730-80A4D898-33EC-4326-A3FE-E340A64410AA Q36515526-BF25352B-B467-4F20-9408-8101670174EA Q36555524-DFC0D2F2-4A65-4FD9-B0E2-8B6861615A3A Q36567448-2A10C495-DC84-4F33-BEE6-3956C4F5EE33 Q36631345-AA5F9CDE-F477-4214-B961-01143AAF0C4D Q36665022-EC6B13A5-2469-47A9-9814-58353BAAADB7 Q36690209-4D6C247D-E05C-4CD3-8FF4-AA6322AA0F61 Q36871685-8D808DDA-63F9-40DD-94B3-2C10FB381056 Q37064737-B029D6A8-345A-4073-BE10-36F398038E99 Q37445211-C7F9B236-A925-4B78-A75F-ECF2F1AB0519 Q37538483-115506C6-669F-4BDE-BFD0-36250E8B4BB2 Q38005622-8BC45E69-E227-4FDB-B19B-F8071D67206A Q38009352-9B6C4C8A-D4BC-4EF7-A448-1C9982FDBE45 Q38036690-AEB7FD26-0BEB-4EA9-98C8-B55AB4A72736 Q38046826-38F33FD9-BF92-4FA6-BB09-B6BEEDB7BA4C Q38089935-91CFD194-EB9D-47A5-8DDC-648D8FA94427 Q38094811-3FA21647-8C2F-4116-9C43-8FE3617AEADC Q38097373-6A6383B0-7B38-4EFE-B9AA-2E55B1C78DB0 Q38107203-FE7B8C38-EE07-41D0-8AE1-415803E83FE8 Q38119260-6B9B82C2-F8D5-48B4-83F9-4A0DF41D2970 Q38125501-6610E190-FC3B-4FD2-9709-550872BE06C7 Q38162286-F19D56D2-58D4-4626-96A8-C3CAFAC60F84 Q38181005-CB23315C-AA68-4193-9FD4-552C076BE686 Q38205964-52260CD1-235E-4BD1-B140-7D041A6D3C9D Q38212571-73421CA8-C90F-41E0-8F62-0E3497C20923

P2860

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

http://www.wikidata.org/entity/Q24630999

description

2012 nî lūn-bûn

@nan

2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Interdisciplinary critique of ...... tion-resistant prostate cancer

@ast

Interdisciplinary critique of ...... tion-resistant prostate cancer

@en

Interdisciplinary critique of ...... tion-resistant prostate cancer

@nl

type

label

Interdisciplinary critique of ...... tion-resistant prostate cancer

@ast

Interdisciplinary critique of ...... tion-resistant prostate cancer

@en

Interdisciplinary critique of ...... tion-resistant prostate cancer

@nl

prefLabel

Interdisciplinary critique of ...... tion-resistant prostate cancer

@ast

Interdisciplinary critique of ...... tion-resistant prostate cancer

@en

Interdisciplinary critique of ...... tion-resistant prostate cancer

@nl

P1433

Q24630999-26831F70-DD5A-4A52-B798-B0B2D02BDB1E

P1476

Q24630999-570362E9-15AB-47D4-8F82-19B7CBCB2FC6

P2093

Q24630999-2CD112B5-3180-40B1-BA34-AD1B97ECAE93

Q24630999-A0A7AC39-69D7-4013-854A-BD450474B684

Q24630999-C35FB166-E8AC-477F-98CF-6D8A2021CB32

Q24630999-F53815BB-62AB-46BB-BA9D-6838C5B9ED80

P2860

Q24630999-02EB538D-6C41-4F47-95C8-F8A032EA0F1D

Q24630999-077C0BB8-0E4F-4D13-96E8-29AACE277147

Q24630999-0A36D614-699F-44CA-BDFA-D84F3064314E

Q24630999-1C983639-7019-4FFC-B4B6-B90FB117A99D

Q24630999-347478FB-85D4-42D0-8CDF-13181EAC6724

Q24630999-3690FEC2-8C90-4299-94F4-EBD305455632

Q24630999-39F585A1-9AFF-4579-ADB2-26B2432AB59A

Q24630999-3A731577-9FAC-4237-9D11-B7DBD8AECB8B

Q24630999-42169B6E-0C35-46F5-B1B7-EE2C3F0E9929

Q24630999-52F9F9DE-C429-4A1F-8C88-9CF4412DE0EA

P304

Q24630999-331CA3A9-4440-4326-B76A-64D88CAA6611

P31

Q24630999-1F1F63BD-5A9C-4B07-995D-7C529FCBB586

P356

Q24630999-61A10FE6-C388-4BB1-9E9C-E41CCE08CAF1

P407

Q24630999-0796B2FD-7665-4111-AEFE-64841240DF3F

P433

Q24630999-FDB84CEB-0784-4178-B708-3A6C170F4E89

P478

Q24630999-813D321C-AE96-49B1-B71B-AD84543E8C09

P577

Q24630999-3063C646-EC77-4524-B572-3FC4961C9B8C

P5875

Q24630999-ED3EA481-78B9-472D-B6A2-3A6CE0B925B1

P698

Q24630999-FA55F9CA-E81C-47C2-A893-3FEC641121D4

P921

Q24630999-45DD43FB-DE4E-42A4-A33B-2848F3C24D4E

P932

Q24630999-91FA159D-89AC-408D-8C82-914E3FDBA56E

P356

P1433

Journal of the National Cancer Institute

P1476

Interdisciplinary critique of ...... tion-resistant prostate cancer

@en

P2093

Chris Parker

http://www.w3.org/2001/XMLSchema#string

Laura Haynes

http://www.w3.org/2001/XMLSchema#string

Marie L Huber

http://www.w3.org/2001/XMLSchema#string

Peter Iversen

http://www.w3.org/2001/XMLSchema#string

P2860

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Immunosenescence: deficits in adaptive immunity in the elderly

Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment, and signaling

The influence of age on T cell generation and TCR diversity

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Immunosenescence and cancer: a review.

Aging, immunity, and tumor susceptibility.

P304

273-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR514

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221735598

http://www.w3.org/2001/XMLSchema#string

P698

22232132

http://www.w3.org/2001/XMLSchema#string

P921

P932

3283534

http://www.w3.org/2001/XMLSchema#string